Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
12 pending office actions • 7 art units • 11 examiners • 0 of 12 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
UNIVERSITE PARIS CITE currently has 11 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are spread across 10 distinct examiners and 7 distinct art units, showing a high level of distribution for a portfolio of this size. This variety suggests that the university's research in Biotechnology & Pharmaceuticals is being reviewed by a diverse group of specialists at the patent office.
LUSI, ELLIS FOLLETT is the busiest examiner for the university, currently managing 2 pending office actions. Given that there are 11 pending office actions in total, the fact that 10 distinct examiners are involved means that most examiners are handling only a single matter for the university. Practitioners must therefore tailor their advocacy to 10 different examiner styles and preferences.
The involvement of 7 distinct art units for 11 pending office actions indicates that the portfolio covers several distinct sub-fields. This requires a prosecution strategy that is sensitive to the specific prior art and legal standards applied across these 7 distinct art units. Successfully navigating 11 pending office actions in this environment requires a flexible approach that can address the unique concerns of 10 distinct examiners and 7 distinct art units.
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (8%) |
| §103 only | 2 (17%) |
| §112 only | 1 (8%) |
| Double-patenting only | 1 (8%) |
| Multi-statute (no §101) | 7 (58%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LUSI, ELLIS FOLLETT | 2 | 63.5% | +53.4% |
| GROSS, JASON PATRICK | 1 | 64.0% | +43.3% |
| HUTTER, GILLIAN A | 1 | 54.5% | +46.2% |
| JAUHARI, SACHI | 1 | 60.0% | +80.0% |
| CONSTANTINE, CHARLES Z | 1 | 58.9% | +49.2% |
| BARRON, SEAN C | 1 | 52.9% | +30.9% |
| BUTTICE, AUDREY L | 1 | 47.9% | +25.9% |
| BRADLEY, CHRISTINA | 1 | 62.6% | +33.3% |
| OSENBAUGH-STEWART, ELIZA W | 1 | 73.0% | +16.7% |
| DENT, ALANA HARRIS | 1 | 44.2% | +32.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18247945 | GDF3 AS BIOMARKER AND BIOTARGET IN POST-ISCHEMIC CARDIAC REMODELING | LUSI, ELLIS FOLLETT | 103d overdue |
| 18273252 | DEVICE FOR MEASURING AND/OR MODIFYING A SURFACE | OSENBAUGH-STEWART, ELIZA W | 13d |
| 18700200 | GIANT ORGANELLES RECOVERY AND USE THEREOF | BARRON, SEAN C | 21d |
| 18032817 | METHOD FOR EVALUATING THE MECHANOBIOLOGICAL PROPERTIES OF A CELL ELEMENT | LUSI, ELLIS FOLLETT | 34d |
| 18857856 | NEW FORMULATION OF ATROPINE | HUTTER, GILLIAN A | — |
| 18571893 | USE OF IL-36 INHIBITORS FOR THE TREATMENT OF NETHERTON SYNDROME | BUTTICE, AUDREY L | — |
| 18552054 | TREM-1 INHIBITORS FOR THE TREATMENT OF MARFAN SYNDROME | BRADLEY, CHRISTINA | — |
| 17904529 | OPTIMIZATION OF PEPTIDE-MELANIN BINDING | D' AMBROSIO, THEA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18247945 | GDF3 AS BIOMARKER AND BIOTARGET IN POST-ISCHEMIC CARDIAC REMODELING | LUSI, ELLIS FOLLETT | 103d overdue |
| 18273252 | DEVICE FOR MEASURING AND/OR MODIFYING A SURFACE | OSENBAUGH-STEWART, ELIZA W | 13d |
| 18003999 | METHODS FOR PREDICTING THE RISK OF RECURRENCE AND/OR DEATH OF PATIENTS SUFFERING FROM A SOLID CANCER AFTER PREOPERATIVE ADJUVANT THERAPY AND RADICAL SURGERY | DENT, ALANA HARRIS | 16d |
| 18700200 | GIANT ORGANELLES RECOVERY AND USE THEREOF | BARRON, SEAN C | 21d |
| 18032817 | METHOD FOR EVALUATING THE MECHANOBIOLOGICAL PROPERTIES OF A CELL ELEMENT | LUSI, ELLIS FOLLETT | 34d |
| 19078397 | Efficient Magnetic Resonance Elastography using Interleaved Motion Encoding | GROSS, JASON PATRICK | — |
| 18857856 | NEW FORMULATION OF ATROPINE | HUTTER, GILLIAN A | — |
| 18730927 | COMPOUND FOR USE IN PREVENTING AND/OR TREATING AN INFECTION CAUSED BY SARS-COV-2 | JAUHARI, SACHI | — |
| Art Unit | Apps |
|---|---|
| 1654 | 2 |
| 1677 | 2 |
| 3797 | 1 |
| 1657 | 1 |
| 1653 | 1 |
| 2881 | 1 |
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19078397 | Efficient Magnetic Resonance Elastography using Interleaved Motion Encoding | GROSS, JASON PATRICK | 3797 | §103 | Non-Final OA | — | Pending | Mar 13, 2025 |
| 18857856 | NEW FORMULATION OF ATROPINE | HUTTER, GILLIAN A | — | §102§103 | Non-Final OA | — | Pending | Oct 18, 2024 |
| 18730927 | COMPOUND FOR USE IN PREVENTING AND/OR TREATING AN INFECTION CAUSED BY SARS-COV-2 | JAUHARI, SACHI | — | §103Other | Non-Final OA | — | Pending | Jul 22, 2024 |
| 18725322 | METHODS OF INDUCING CELL DEATH OF A POPULATION OF SOLID TUMOR CELLS | CONSTANTINE, CHARLES Z | 1657 | §112 | Non-Final OA | — | Pending | Jun 28, 2024 |
| 18700200 | GIANT ORGANELLES RECOVERY AND USE THEREOF | BARRON, SEAN C | 1653 | §102§103 | Final Rejection | 21d | Pending | Apr 10, 2024 |
| 18571893 | USE OF IL-36 INHIBITORS FOR THE TREATMENT OF NETHERTON SYNDROME | BUTTICE, AUDREY L | — | §102§103§112 | Non-Final OA | — | Pending | Dec 19, 2023 |
| 18552054 | TREM-1 INHIBITORS FOR THE TREATMENT OF MARFAN SYNDROME | BRADLEY, CHRISTINA | 1654 | §103§112 | Non-Final OA | — | Pending | Sep 22, 2023 |
| 18273252 | DEVICE FOR MEASURING AND/OR MODIFYING A SURFACE | OSENBAUGH-STEWART, ELIZA W | 2881 | §102§103§112 | Non-Final OA | 13d | Pending | Jul 19, 2023 |
| 18032817 | METHOD FOR EVALUATING THE MECHANOBIOLOGICAL PROPERTIES OF A CELL ELEMENT | LUSI, ELLIS FOLLETT | 1677 | §103§112 | Non-Final OA | 34d | Pending | Apr 20, 2023 |
| 18247945 | GDF3 AS BIOMARKER AND BIOTARGET IN POST-ISCHEMIC CARDIAC REMODELING | LUSI, ELLIS FOLLETT | 1677 | §101§102§103§112 | Non-Final OA | 103d overdue | Pending | Apr 05, 2023 |
| 18003999 | METHODS FOR PREDICTING THE RISK OF RECURRENCE AND/OR DEATH OF PATIENTS SUFFERING FROM A SOLID CANCER AFTER PREOPERATIVE ADJUVANT THERAPY AND RADICAL SURGERY | DENT, ALANA HARRIS | 1643 | DP | Final Rejection | 16d | Pending | Dec 30, 2022 |
| 17904529 | OPTIMIZATION OF PEPTIDE-MELANIN BINDING | D' AMBROSIO, THEA | 1654 | §102§103§112 | Non-Final OA | — | Pending | Aug 18, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial